A Phase 2 interventional study of irbesartan and placebo in Hypertension, sponsored by Ligand Pharmaceuticals. Completed at 40 sites in United States. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2011-09-16.
Sponsored by Ligand Pharmaceuticals · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 2,031 studies in Hypertension with a site in United States — 272 open to participants now, 369 under way, 16 of them phase 3. Hypertension · United States.
Among the 2,031 studies in Hypertension with a site in United States, this one is the 544th largest by enrollment of the 1,779 interventional ones that give a count, is one of 90 that started in 2008, is one of 170 in phase 2, and was the 399th registered.
6,122 studies on the registry are indexed under Hypertension; 913 are open to participants now.
Browse Hypertension studies →272 of the 2,031 studies in Hypertension with a site in United States are open now. Recruiting first, the newest first:
Vanderbilt University Medical Center · Sites in United States
Ages 18+
University of California, San Francisco · Sites in United States
Ages 18+
University of Alabama at Birmingham · Sites in United States
Ages 16–56 · Women only
The University of Texas at Arlington · Sites in United States
Ages 26–49
CRISPR Therapeutics AG · Sites in United States, Australia, United Kingdom
Ages 18–75
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 563 Hypertension studies recruiting now, 266 (47%) set no upper age limit and 200 (36%) stop at 75 or younger; 40 take children under 18; 139 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
2,031 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 147 · Phase 2 216 · Phase 3 214 · Phase 4 188
First in 1973; this study’s year is marked. 90 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 261 is above the median of 100 across 4,579 interventional studies indexed under Hypertension.
Median enrollment 100 across the 1,779 interventional studies, 200 across the 238 observational. Of the 1,514 that completed or were terminated, 578 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
461 of 2,031 have an industry lead sponsor. The 10 most frequent:
This study is registered under Ligand Pharmaceuticals, one of the names counted as Ligand Pharmaceuticals Incorporated. Under that name alone:
Ligand Pharmaceuticals is the lead sponsor of 21 studies on the registry; none are open to participants now.
Ligand Pharmaceuticals Incorporated has 2 studies filed under Hypertension — fewer than ten, so there is no comparison to draw.
143 of the studies in Hypertension with a site in United States that are under way reach primary completion within a year, 6 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03683186Phase 3United TherapeuticsA Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension | 2026-12 |
| NCT04971720Phase 3University of Alabama at BirminghamPRECISION-BP: Precision Chronopharamacotherapy Targeting NP-RAAS-BP Rhythm Axis | 2027-01-01 |
| NCT06948422Phase 3Eli Lilly and CompanyA Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening) | 2027-09 |
| NCT06948435Phase 3Eli Lilly and CompanyA Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1 | 2027-09 |
| NCT06952530Phase 3Eli Lilly and CompanyA Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL2 | 2027-09 |
Add all 143 to your calendar (.ics) → With an account.
Among the 2,031 studies in Hypertension with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to learn which doses of PS433540 should be given to patients with high blood pressure to lower their blood pressure. This study will also examine how safe PS433540 is when taken by patients with high blood pressure. Approximately 720 patients will be evaluated so that about 375 patients will be entered into the treatment phase of the study and be given PS433540.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Irbesartan 300 mg once daily
Drug: irbesartan
Blinded Placebo Treatment
Drug: placebo
PS433540 200mg once daily
Drug: PS433540
PS433540 400mg once daily
Drug: PS433540
PS433540 800mg once daily
Drug: PS433540
300 mg (2 x 150 mg capsules) once daily for 12 weeks
Also known as: Avapro
placebo capsules once daily for 12 weeks
200 mg (2 x 100 mg capsules) once daily for 12 weeks
400 mg (4 x 100 mg capsules) once daily for 12 weeks
800 mg (8 x 100 mg capsules) once daily for 12 weeks
Change From Baseline in Mean Seated Systolic Blood Pressure (SBP) Following 12 Weeks of Treatment With PS433540 200 mg, 400 mg, 800 mg and Placebo.
Time frame: 12 weeks
Change From Baseline in Mean Seated Diastolic Blood Pressure (DBP) Following 12 Weeks of Treatment With PS433540 200 mg, 400 mg, 800 mg and Placebo.
Time frame: 12 weeks
The Percentage of Patients Treated With Each Dose of PS433540 Who Achieved Blood Pressure Control, Defined as <140/90 mmHg, After 12 Weeks of Treatment.
Time frame: 12 weeks
| Milestone | Irbesartan 300mg | Placebo | PS433540 200mg | PS433540 400mg | PS433540 800mg |
|---|---|---|---|---|---|
| Started | 58 | 59 | 58 | 58 | 28 |
| Completed | 44 | 39 | 55 | 48 | 20 |
| Not completed | 14 | 20 | 3 | 10 | 8 |
| mm Hg | Irbesartan 300mg | Placebo | PS433540 200mg | PS433540 400mg | PS433540 800mg |
|---|---|---|---|---|---|
| Change From Baseline in Mean Seated Systolic Blood Pressure (SBP) Following 12 Weeks of Treatment With PS433540 200 mg, 400 mg, 800 mg and Placebo. | -10.7 ± 14.32 | 1.8 ± 14.16 | -13.2 ± 13.61 | -14.2 ± 11.90 | -23.4 ± 18.70 |
| mm Hg | Irbesartan 300mg | Placebo | PS433540 200mg | PS433540 400mg | PS433540 800mg |
|---|---|---|---|---|---|
| Change From Baseline in Mean Seated Diastolic Blood Pressure (DBP) Following 12 Weeks of Treatment With PS433540 200 mg, 400 mg, 800 mg and Placebo. | -7.1 ± 9.19 | 0.2 ± 9.68 | -7.2 ± 8.34 | -9.2 ± 9.10 | -14.3 ± 10.53 |
| participants | Irbesartan 300mg | Placebo | PS433540 200mg | PS433540 400mg | PS433540 800mg |
|---|---|---|---|---|---|
| The Percentage of Patients Treated With Each Dose of PS433540 Who Achieved Blood Pressure Control, Defined as <140/90 mmHg, After 12 Weeks of Treatment. | 17 | 5 | 21 | 28 | 16 |
Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Irbesartan 300mg | — | 0/58 (0%) | 19/58 (32.8%) |
| Placebo | — | 0/59 (0%) | 20/59 (33.9%) |
| PS433540 200mg | — | 0/58 (0%) | 10/58 (17.2%) |
| PS433540 400mg | — | 1/58 (1.7%) | 25/58 (43.1%) |
| PS433540 800mg | — | 0/28 (0%) | 17/28 (60.7%) |
| Event | Irbesartan 300mg | Placebo | PS433540 200mg | PS433540 400mg | PS433540 800mg |
|---|---|---|---|---|---|
| Squamous cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/58 | 0/59 | 0/58 | 1/58 | 0/28 |
| Event | Irbesartan 300mg | Placebo | PS433540 200mg | PS433540 400mg | PS433540 800mg |
|---|---|---|---|---|---|
| HeadacheNervous system disorders | 4/58 | 10/59 | 0/58 | 3/58 | 2/28 |
| DizzinessNervous system disorders | 2/58 | 2/59 | 0/58 | 2/58 | 3/28 |
| Oedema PeripheralGeneral disorders | 2/58 | 1/59 | 2/58 | 4/58 | 3/28 |
| Abdominal PainGastrointestinal disorders | 0/58 | 1/59 | 1/58 | 0/58 | 2/28 |
| DiarrhoeaGastrointestinal disorders | 1/58 | 0/59 | 1/58 | 1/58 | 2/28 |
| NauseaGastrointestinal disorders | 1/58 | 0/59 | 0/58 | 1/58 | 2/28 |
| FatigueGeneral disorders | 3/58 | 1/59 | 0/58 | 4/58 | 0/28 |
| Injury, Poisoning and Procedural ComplicationsInjury, poisoning and procedural complications | 2/58 | 2/59 | 2/58 | 4/58 | 0/28 |
| Eye DisordersEye disorders | 0/58 | 3/59 | 0/58 | 0/58 | 0/28 |
| MigraineNervous system disorders | 2/58 | 3/59 | 0/58 | 2/58 | 0/28 |
| Age, Categorical(Participants) | Irbesartan 300mg | Placebo | PS433540 200mg | PS433540 400mg | PS433540 800mg | Total |
|---|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 53 | 52 | 50 | 48 | 28 | 231 |
| >=65 years | 5 | 7 | 8 | 10 | 0 | 30 |
| Age Continuous(years) | Irbesartan 300mg | Placebo | PS433540 200mg | PS433540 400mg | PS433540 800mg | Total |
|---|---|---|---|---|---|---|
| Mean | 51.5 ± 8.97 | 54.2 ± 8.12 | 53.2 ± 10.58 | 53.4 ± 10.71 | 51.4 ± 9.92 | 52.9 ± 9.66 |
| Sex: Female, Male(Participants) | Irbesartan 300mg | Placebo | PS433540 200mg | PS433540 400mg | PS433540 800mg | Total |
|---|---|---|---|---|---|---|
| Female | 23 | 30 | 27 | 26 | 17 | 123 |
| Male | 35 | 29 | 31 | 32 | 11 | 138 |
| Region of Enrollment(participants) | Irbesartan 300mg | Placebo | PS433540 200mg | PS433540 400mg | PS433540 800mg | Total |
|---|---|---|---|---|---|---|
| United States | 58 | 59 | 58 | 58 | 28 | 261 |
The record gives a start of Mar 2008, a primary completion of Nov 2008 and a completion of Dec 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Sep 2011, 2 years 10 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Sparsentan